|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
|
|
|
Jim Huang, PhD, reviews how a pediatric formulation should consider the following factors: difference in physiological and pharmacokinetic of patient populations, dosage form selection, route of administration, dose accuracy, dose flexibility, drug and excipient tolerability (safety and toxicity), patient compliance (palatability/swallowability), stability, and drug accessibility.
|
|
|
Mei Mei Tian, PhD, explains how the xB3 platform has the potential to support development of treatments for CNS diseases that can treat thousands of patients in the years ahead.
|
|
|
Stephanie Reed, PhD, Carissa Smoot, and Dennis Shull describe how PGSU ultimately offers many advantages over other polymers for long-acting implantables, particularly for high-loading, long-duration implants that are gaining interest in the pharmaceutical industry.
|
|
|
|
|
|
|
|
|

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support. Our objective is to help our customers reduce time and risk in research and development, so their drug achieves a higher chance of success. Our VitalDose® Ethylene-Vinyl Acetate (EVA) copolymer drug-delivery platform is an enabling technology for drug-eluting implants, inserts and transdermal films. The platform is flexible and customizable to address a variety of formulation challenges when it comes to tailoring the release rate of your drug. Click here for more.
|
|
|
|
|
|
 |
|
BioNTech SE and InstaDeep Ltd recently announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning (ML) technology to develop….
|
|
 |
|
Foster Corporation recently announce a new business relationship with Aran Biomedical, a global leader in biomaterial product solutions for implantable medical devices…..
|
|
 |
|
Recipharm, a leading contract development and manufacturing organization (CDMO), recently announced that it has signed a letter of intent with Moderna, a US-based biotech company, to formulate, fill, and….
|
|
 |
|
Kieran Coffey, Technical Lead at Pfizer CentreOne’s Newbridge facility, discusses the benefits of small-scale processing for process development of tablet products.
|
|
|
|
|
Upcoming eNewsletter Features:
December 9 – Drug Delivery
December 16 – Parenteral Contract Manufacturing
|
|
|
|
|
|
|
|